InspireMD, Inc. (NSPR)
NCM · Medical Devices
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid Stent System; and SwitchGuard neuroprotection system to provide flow reversal of cerebral protection in carotid interventions, as well as treating acute stroke with tandem lesions. The company was founded in 2005 and is headquartered in Miami, Florida.
Peers in Medical Devices
All in industry →Abbott Laboratories
Stryker Corporation
Medtronic plc
Boston Scientific Corporation
Edwards Lifesciences Corporation
GE HealthCare Technologies Inc.
Koninklijke Philips N.V.
DexCom, Inc.
STERIS plc
Zimmer Biomet Holdings, Inc.
Recent press releases
April 2026
NSPR proposes increasing authorized shares and electing three new directors
# 📜 What This Document Is 📰 This document is a **Proxy Statement (DEF 14A)**. In simple terms, think of it as a comprehensive guide and formal invitation for the company's annual meeting of stockholders. The purpose is to inform shareholders about what matters will be voted on, who runs the compa
InspireMD Seeks to Increase Authorized Shares to 250 Million
# 🧾 What This Document Is This is a **PRELIMINARY PROXY STATEMENT** (Form PRE 14A) for InspireMD, Inc. Think of it as the official "meeting agenda" and instruction booklet sent to shareholders ahead of an important vote. Its purpose is to give shareholders the information they need to vote on com
SEC filings
All filings →Insider trades
All insider trades →InspireMD, Inc. has no reported insider trades in the last 90 days.